Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway
- 1 May 2014
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 40 (4) , 507-512
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2012
- Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health InitiativeGynecologic Oncology, 2011
- Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?Obstetrics and Gynecology International, 2010
- The endometrium – from estrogens alone to TSECsClimacteric, 2009
- Resistance to chemotherapy and hormone therapy in endometrial cancerEndocrine-Related Cancer, 2009
- The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted TherapiesCancer Control, 2009
- Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaborationAnnals of Oncology, 2006
- Molecular and Pathologic Aspects of Endometrial CarcinogenesisJournal of Clinical Oncology, 2006
- Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial PrecancersJNCI: Journal of the National Cancer Institute, 2000
- Two pathogenetic types of endometrial carcinomaGynecologic Oncology, 1983